

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b>  <b>IN AN APPLICATION</b>  (Use several sheets if necessary)	Docket Number: 12695.19USWO	Application Number: 10/549,505
	Applicant: Diakur et al.	
	Filing Date: June 27, 2006	Group Art Unit: 1614

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	3,282,778	11/1/1966	Lobel			
	6,043,259	3/28/2000	Dhalla et al.			
	6,051,587	04/18/2000	Dakashinamurti et al.			
	6,339,085 B1	01/15/2002	Haque			
	6,417,204 B1	07/09/2002	Haque			
	6,489,345	12/3/2002	Sethi			
	6,548,519 B1	04/15/2003	Haque			
	6,586,414	07/01/2003	Haque et al.			
	6,667,315 B2	12/23/2003	Haque			
	6,677,356	1/13/2004	Sethi et al.			
	6,780,997 B2	08/24/2004	Haque			
	6,861,439 B2	03/01/2005	Haque et al.			
	6,867,215 B2	03/15/2005	Haque			
	6,890,943 B2	05/10/2005	Haque			
	6,897,228 B2	05/24/2005	Haque			
	7,105,673 B2	09/12/2006	Haque			
	7,115,625 B2	10/03/2006	Sethi et al.			
	7,115,626 B2	10/03/2006	Sethi et al.			
	7,125,889 B2	10/24/2006	Sethi et al.			
	7,132,430 B2	11/07/2006	Sethi et al.			
	7,144,892 B2	12/05/2006	Sethi et al.			
	7,148,233 B2	12/12/2006	Sethi et al.			
	7,230,009 B2	06/12/2007	Haque et al.			
	2004/0121988 A1	06/24/2004	Haque et al.			
	2004/0171588 A1	09/02/2004	Haque			
	2004/0186077	09/23/2004	Diakur et al.			
	2004/0235907	11/25/2004	Sethi			
	2005/0107443 A1	05/19/2005	Haque			
	2006/0019929 A1	01/26/2006	Friesen			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CA/

EXAMINER	/Charanjit Aulakh/	DATE CONSIDERED	05/08/2008
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.			

<b>FORM 1449*</b>  <b>INFORMATION DISCLOSURE STATEMENT</b>  <b>IN AN APPLICATION</b>  (Use several sheets if necessary)	Docket Number: 12695.19USWO	Application Number: 10/549,505
	Applicant: Diakur et al.	
	Filing Date: June 27, 2006	Group Art Unit: 1614

	2006/0035864	02/16/2006	Friesen			
	2006/0094748 A1	05/04/2006	Haque et al.			
	2006/0094749 A1	05/04/2006	Haque et al.			
	2006/0094761 A1	05/04/2006	Haque et al.			
	2006/0148763 A1	07/06/2006	Friesen et al.			
	2007/0032456	02/08/2007	Friesen			
	2007/0060549	03/15/2007	Friesen			
	2007/0142270 A1	06/21/2007	Haque et al.			
	2007/0149485 A1	07/12/2007	Friesen			
	2007/0167411 A1	07/19/2007	Reimer			
	2007/0243249 A1	10/18/2007	Reimer			
	2007/0249562 A1	10/25/2007	Reimer			
	3,206,463	09/14/1965	Baetz			
	3,910,921	10/07/1975	Esanu			
	3,987,177	10/19/1976	Giudicelli et al.			
	4,032,534	06/28/1977	Chodkiewicz			
	4,036,844	07/19/1977	Thorne et al.			
	4,053,607	10/11/1977	Thorne et al.			
	4,137,316	01/30/1979	Esanu			
	4,167,562	09/11/1979	Evers			
	4,361,570	11/30/1982	Fici			
	4,369,172	01/18/1983	Schor et al.			
	4,374,841	02/22/1983	Descamps et al.			
	4,515,771	05/07/1985	Fine			
	4,567,179	01/28/1986	Lombardino			
	4,569,938	02/11/1986	Esanu			
	4,569,939	02/11/1986	Esanu			
	4,581,363	04/08/1986	Esanu			
	4,605,741	08/12/1986	Zagnoli et al.			
	4,696,920	09/29/1987	Bentzen et al.			
	4,730,042	03/08/1988	Hege et al.			
	4,735,950	04/05/1988	Esanu			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CA/

EXAMINER      /Charanjit Aulakh/	DATE CONSIDERED      05/08/2008
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b>  <b>IN AN APPLICATION</b>  (Use several sheets if necessary)	Docket Number: 12695.19USWO	Application Number: 10/549,505
	Applicant: Diakur et al.	
	Filing Date: June 27, 2006	Group Art Unit: 1614

	4,735,956	08/05/1988	Baldwin et al.			
	4,837,239	06/06/1989	Benjamin et al.			
	4,843,071	06/27/1989	Hohenwarter			
	4,962,121	10/09/1990	Hamberger et al.			
	5,001,115	03/19/1991	Sloan			
	5,053,396	10/01/1991	Blass			
	5,118,505	06/02/1992	Költringer			
	5,130,324	07/14/1992	Ulrich et al.			
	5,132,115	07/21/1992	Wolter et al.			
	5,210,083	05/11/1993	Pfaffmann			
	5,213,813	05/25/1993	Kornecki et al.			
	5,254,557	10/19/1993	Buckle et al.			
	5,254,572	10/19/1993	Serfontein			
	5,272,165	12/21/1993	Ulrich et al.			
	5,278,154	01/11/1994	Lacoste et al.			
	5,288,716	02/22/1994	Speck			
	5,326,757	07/05/1994	Demopoulos			
	5,328,453	07/12/1994	Sibalis			
	5,372,999	12/13/1994	Schneider et al.			
	5,385,937	01/31/1995	Stamler et al.			
	5,420,112	05/30/1995	Lewis et al.			
	5,441,972	08/15/1995	Ogata et al.			
	5,504,090	04/02/1996	Neely			
	5,563,126	10/08/1996	Allen et al.			
	5,569,459	10/29/1996	Shlyankevich			
	5,569,648	10/29/1996	Lewis et al.			
	5,631,271	05/20/1997	Serfontein			
	5,633,228	05/27/1997	Lewis et al.			
	5,648,335	07/15/1997	Lewis et al.			
	5,728,684	03/17/1998	Cheng et al.			
	5,733,884	03/31/1998	Barbul et al.			
	5,733,916	03/31/1998	Neely			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CA/

EXAMINER /Charanjit Aulakh/	DATE CONSIDERED 05/08/2008
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

<b>FORM 1449*</b>  <b>INFORMATION DISCLOSURE STATEMENT</b>  <b>IN AN APPLICATION</b>  (Use several sheets if necessary)	Docket Number: 12695.19USWO	Application Number: 10/549,505
	Applicant: Diakur et al.	
	Filing Date: June 27, 2006	Group Art Unit: 1614

	5,770,215	06/23/1998	Moshyedi			
	5,795,873	08/18/1998	Allen			
	5,804,163	09/08/1998	Gibby et al.			
	5,804,594	09/08/1998	Murad			
	5,833,998	11/10/1998	Biedermann et al.			
	5,834,446	11/10/1998	Dow et al.			
	5,840,685	11/24/1998	Fujii et al.			
	5,847,008	12/08/1998	Doebber et al.			
	5,858,017	01/12/1999	Demopoulos et al.			
	5,859,051	01/12/1999	Adams et al.			
	5,874,420	02/23/1999	Pelleg			
	5,874,443	02/23/1999	Kiely et al.			
	5,888,514	03/30/1999	Weisman			
	5,944,020	08/31/1999	Markov et al.			

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	831,350	01/14/1976	BE				X
	863,754	05/29/1978	BE				X
	561 183	04/30/1975	CH				X
	1 958 226	05/27/1970	DE				
	37 05 549 A1	09/01/1988	DE				
	43 44 751 A1	06/29/1995	DE				X
	24 61 742 A	07/08/1976	DT				X
	0 121 036 A1	10/10/1984	EP				
	0 144 051 A2	06/12/1985	EP				
	0 270 026 A2	06/08/1988	EP				
	0 416 248 A2	03/13/1991	EP				
	0 891 719 A1	01/20/1999	EP				
	846,376	03/26/1941	FR				
	1,323,941	12/15/1963	FR				
	5,552 M	12/26/1967	FR				X

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CA/

EXAMINER	/Charanjit Aulakh/	DATE CONSIDERED	05/08/2008
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.			

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b>  <b>IN AN APPLICATION</b>  (Use several sheets if necessary)	Docket Number: 12695.19USWO	Application Number: 10/549,505
	Applicant: Diakur et al.	
	Filing Date: June 27, 2006	Group Art Unit: 1614

	5,801 M	03/28/1968	FR				
	6,453 M	12/16/1968	FR				X
	1,579,544	08/29/1969	FR				
	2,034,539	12/11/1970	FR				
	2,101,010	03/31/1972	FR				X
	2,255,883	07/25/1975	FR				X
	2,428,640	01/11/1980	FR				X
	1 013 939	12/22/1965	GB				
	1 172 800	12/03/1969	GB				
	1 201 014	08/05/1970	GB				
	1 297 080	11/22/1972	GB				
	1 360 536	07/17/1974	GB				
	1 493 993	12/07/1977	GB				
	2 254 556 A	10/14/1992	GB				
	48-21959	07/02/1973	JP				X
	54-17130	02/08/1979	JP				X
	10-158244	06/16/1998	JP			Abstract	
	2000-26295	01/25/2000	JP			Abstract	
	WO 83/00085	01/20/1983	PCT				
	WO 91/19500	12/26/1991	PCT			Abstract	
	WO 94/18965	09/01/1994	PCT				
	WO 96/12487	05/1996	PCT				
	WO 98/28310	07/02/1998	PCT				
	WO 99/03365	01/28/1999	PCT				
	WO 99/53928	10/28/1999	PCT				
	WO 2005/060975	07/07/2005	PCT				
	WO 2006/005173	01/19/2006	PCT				
	WO 2006/026868	03/16/2006	PCT				
	WO 2006/056079	06/01/2006	PCT				
	WO 2006/058411	06/08/2006	PCT				
	WO 2006/102748	10/05/2006	PCT				
	WO 2006/136004	12/28/2006	PCT				

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CA/

EXAMINER	/Charanjit Aulakh/	DATE CONSIDERED	05/08/2008
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.			

<b>FORM 1449*</b>  <b>INFORMATION DISCLOSURE STATEMENT</b>  <b>IN AN APPLICATION</b>  (Use several sheets if necessary)	Docket Number: 12695.19USWO	Application Number: 10/549,505
	Applicant: Diakur et al.	
	Filing Date: June 27, 2006	Group Art Unit: 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Arbuzov, S., "Pharmacologocical Properties of the Products of the Condensation of Phenamine with Some Metabolites", <i>Farmakol. Toksikol.</i> , Vol. 31, No. 3, pp. 373-376 (1968) (Abstract only).
		Arbuzov, S., "Synthesis and Pharmacological Investigation of Some New Compounds Related Structurally to Some Natural Metabolites", <i>Conf. Hug. Ther. Invest. Pharmacol., Soc. Pharmacol. Hung.</i> , 489-502 (1966) (Abstract only)
		Aybak, M. et al., "Effect of Oral Pyridoxine Hydrochloride Supplementation on Arterial Blood Pressure in Patients with Essential Hypertension", <i>Drug Res.</i> , Vol. 45, No. 12, pp. 1271-1273 (1995).
		"B Vitamins May Cut Heart Disease Risk", <i>Harvard Health Letter</i> , 1 page (1998)
		Baliga, B. et al., "Hyperhomocysteinemia in Type 2 Diabetes Mellitus: Cardiovascular Risk Factors and Effect of Treatment with Folic Acid and Pyridoxine", <i>Endocrine Practice</i> , Vol. 6, No. 6, pp. 435-441 (November/December 2000).
		Barrett, S., "Homocysteine: A Cardiovascular Risk Factor Worth Considering", <a href="http://www.quackwatch.com/03HealthPromotion/homocysteine.html">http://www.quackwatch.com/03HealthPromotion/homocysteine.html</a> , 2 pages (©1997)
		Bennett, R. et al., "Vitamin B <sub>6</sub> -Phosphonic Acids", <i>Journal of Medicinal and Pharmaceutical Chemistry</i> , Vol. 1, No. 3, pp. 213-221 (1959).
		Bernstein, A., "Vitamin B <sub>6</sub> in Clinical Neurology", <i>Annals of New York Academy of Sciences</i> , Vol. 585, pp. 250-260 (1990)
		Berger, A.R. et al., "Dose response, coasting, and differential fiber vulnerability in human toxic neuropathy: A prospective study of pyridoxine neurotoxicity", <i>Neurology</i> , Vol. 42, No. 7, pp. 1367-1370 (July 1992)
		Bhagavan, H. et al., "Effect of Postweanling Pyridoxine Deficiency on Growth and Concentration of the Coenzyme Pyridoxal-5'-phosphate in Heart, Kidneys, Lungs, and Adrenals in Rats", <i>Pediat. Res.</i> , Vol. 10, pp. 730-732 (1976).
		Bode, W. et al., "Pyridoxal-5'-Phosphate and Pyridoxal Biokinetics in Male Wistar Rats Fed Graded Levels of Vitamin B-6", <i>J. Nutr.</i> , Vol. 121, No. 11, pp. 1738-1745 (November 1991)
		Bundgaard, Design and Application of Prodrugs in A Textbook of Drug Design and Development (Krogsgaard-Larson & Bundgaard, eds., Hardwood Academic Publishers, Reading, United Kingdom (1991)
		Chasan-Taber, L. et al., "A Prospective Study of Folate and Vitamin B <sub>6</sub> and Risk of Myocardial Infarction in US Physicians", <i>Journal of the American College of Nutrition</i> , Vol. 15, No. 2, pp. 136-143 (April 1996)
		Cho, Y. et al., "In Vivo Evidence for a Vitamin B-6 Requirement in Carnitine Synthesis", <i>J. Nutr.</i> , Vol. 120, pp. 258-265 (1990)
		"Computer Generated Search Reports", 70 pages (May 1999)
		Ebadi, M. et al., "Convulsant Activity of Pyridoxal Sulphate and Phosphonoethyl Pyridoxal: Antagonism by GABA and its Synthetic Analogues", <i>Neuropharmacology</i> , Vol. 22, No. 7, pp. 865-873 (1983)
		Ellis, J. et al., "Prevention of Myocardial Infarction by Vitamin B <sub>6</sub> ", <i>Res. Commun. Molec. Pathol. Pharmacol.</i> , Vol. 89, No. 2, pp. 208-220 (August 1995)
		Folsom, A. et al., "Clinical Investigation and Reports: Prospective Study of Coronary Heart Disease Incidence in Relation to Fasting Total Homocysteine, Related Genetic Polymorphisms, and B Vitamins: The Atherosclerosis Risk in Communities (ARIC) Study", <i>Circulation</i> , Vol. 98, pp. 204-210 (July 21, 1998).
		Fonda, M., "Interaction of Pyridoxal Analogues with Glutamate Apodecarboxylase and Aspartate Apoaminotransferase", <i>The Journal of Biological Chemistry</i> , Vol. 246, No. 7, pp. 2230-2240 (1971)
		Harada, K. et al., "Studies on Vitamin B <sub>6</sub> . (IV) Behavior of Pyridoxal Acylates in the Body After Parenteral Administration", <i>Vitamins Journal of the Vitamin Society of Japan</i> , Vol. 45, No. 2, pp. 69-75 (February 1972)
		Hathcock, J., "Vitamins and minerals: efficacy and safety", <i>Am J Clin Nutr</i> , Vol. 66, pp. 427 - 437 (1997)
		Hoover, D.M. et al., "Ultrastructural Lesions of Pyridoxine Toxicity in Beagle Dogs", <i>Vet. Pathol.</i> , Vol. 18, pp. 769-777 (1981)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CA/

EXAMINER	/Charanjit Aulakh/	DATE CONSIDERED	05/08/2008
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.			

<b>FORM 1449*</b>  <b>INFORMATION DISCLOSURE STATEMENT</b>  <b>IN AN APPLICATION</b>  (Use several sheets if necessary)	Docket Number: 12695.19USWO	Application Number: 10/549,505
	Applicant: Diakur et al.	
	Filing Date: June 27, 2006	Group Art Unit: 1614

	Kim, Y. et al., "Synthesis and Structure-Activity Relationships of Pyridoxal-6-arylo-5'-phosphate and Phosphonate Derivatives as P2 Receptor Antagonists", <i>Drug Development Research</i> , Vol. 45, pp. 52-66 (1998)
	Kok, F. et al., "Low Vitamin B <sub>6</sub> Status in Patients with Acute Myocardial Infarction", <i>Am. J. Cardiol.</i> , Vol., 63, pp. 513-516 (March 1, 1989)
	Korytnyk, W., "Pyridoxine Chemistry. VI. Homologs of Pyridoxol and of 5-Pyridoxic Acid", <i>Dept. of Exp. Therapeutics, Roswell Park Memorial Institute, Buffalo, New York</i> , Vol 8, pp. 112-115 (1965)
	Korytnyk, W. et al., "Synthesis and Antagonist Properties of Pyridoxol Analogs Modified in the 5 Position", <i>Pyridoxal Analogs, Dept. of Exp. Therapeutics, Roswell Park Memorial Institute, Buffalo, New York</i> , Vol. 10, pp. 345-350 (May 1967)
	Korytnyk et al., "Schiff Bases of Pyridoxal: Their Structure and the Stabilization of their Ring-Chain Tautomeric Forms by Acylation, <i>Tetrahedron</i> , 26 (23), 5415-5425 (1970)
	Korytnyk et al., "Selective Modifications of the 4-Position of Pyridoxol. I. Extension and branching of the 4-side Chain", <i>Dept. of Exp. Therapeutics, Roswell Park Memorial Institute, Buffalo, New York</i> , Vol. 13, pp. 187-191 (March 1970)
	Krinke, G. et al., "Pyridoxine Megavitaminosis: An Analysis of the Early Changes Induced with Massive Doses of Vitamin B <sub>6</sub> in Rat Primary Sensory Neurons", <i>J. Neuropathol. Exp. Neurol.</i> , Vol. 44, No. 7, pp. 117-129 (March 1985)
	Kubyskhin, V. et al., "Comparative characteristics of the arrhythmic syndrome and the possibility for its coenzyme correction in dilated and hypertrophic cardiomyopathy", <i>Ter. Arkh.</i> 61(9): 82-85 (1989).
	Lal, K. et al., "Hypotensive action of 5-HT receptor agonists in the vitamin B <sub>6</sub> -deficient hypertensive rat", <i>Eur. J. Pharmacol.</i> , Vol. 234, Nos. 2/3, pp. 183-189 (April 1993)
	Lal, K. et al., "Calcium channels in vitamin B <sub>6</sub> deficiency-induced hypertension", <i>Journal of Hypertension</i> , Vol. 11, No. 12, pp. 1357-1362 (December 1993)
	Lal, K. et al., "The effect of vitamin B <sub>6</sub> on the systolic blood pressure of rats in various animal models of hypertension", <i>Journal of Hypertension</i> , Vol. 14, No. 3, pp. 355-363 (March 1996)
	Levy, H. et al., "Pyridoxine Deficiency in Congestive Heart Failure", <i>P.S.E.B.M.</i> , Vol. 101, pp. 617-621 (1959)
	Manore, M. et al., "Changes In Plasma Pyridoxal Phosphate (PLP) In Diabetic (D), Hypertensive (HTN) and Hypertensive-diabetic (HTN-D) Men Fed A Constant Vitamin B-6 (B6) Diet", <i>FASEB J</i> , Abstract 1254 (1991).
	Markov, A. et al., "Hemodynamic, electrocardiographic, and metabolic effects of fructose diphosphate on acute myocardial ischemia", <i>American Heart Journal</i> , Vol. 100, No. 5, pp. 639 - 646 (November 1980)
	Mendelsohn, A. et al., "Hemodynamic and Clinical Effects of Oral Levodopa in Children With Congestive Heart Failure", <i>JACC</i> , Vol. 30, No. 1, pp. 237-242 (July 1997).
	Merrill, Jr. et al. A. et al., "Diseases associated with defects in vitamin B <sub>6</sub> metabolism or utilization", <i>Ann. Rev. Nutr.</i> , Vol. 7, pp. 137-156 (1987)
	Miura, R. et al., "Reactions of Phosphonate Analogs of Pyridoxal Phosphate with Apo-aspartate Aminotransferase", <i>Archives of Biochemistry and Biophysics</i> , Vol. 270, N. 2, pp. 526-540 (1989)
	Mulvaney, D. et al., "Electrocardiographic changes in vitamin B <sub>6</sub> deficient rats", <i>Cardiovascular Research</i> , Vol. 13, pp. 506-513 (1979).
	Omenn, G. et al., "Preventing Coronary Heart Disease", <i>Circulation</i> , Vol. 97, pp. 421-424 (1998)
	Paulose, C. et al., "Sympathetic Stimulation and Hypertension in the Pyridoxine-Deficient Adult Rat", <i>Hypertension</i> , Vol. 11, No. 4, pp. 387-391 (April 1988)
	Rao, R. et al., "Failure of Pyridoxine to Improve Glucose Tolerance in Diabetics", <i>Journal of Clinical Endocrinology &amp; Metabolism</i> , Vol. 50, No. 1, pp. 198-200 (January 1980).
	Rimm, E. et al., "Folate and Vitamin B <sub>6</sub> From Diet and Supplements in Relation to Risk of Coronary Heart Disease Among Women", <i>JAMA</i> , Vol. 279, No. 5, pp. 359-364 (February 4, 1998)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CA/

EXAMINER	/Charanjit Aulakh/	DATE CONSIDERED	05/08/2008
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.			

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b>  <b>IN AN APPLICATION</b>  (Use several sheets if necessary)	Docket Number: 12695.19USWO	Application Number: 10/549,505
	Applicant: Diakur et al.	
	Filing Date: June 27, 2006	Group Art Unit: 1614

	Sakuragi, T. et al., "The Synthesis of Long Chain Fatty Acid Derivatives of the Vitamin B <sub>6</sub> Group", <i>J. Am. Chem. Soc.</i> , Vol. 78, pp. 839-842 (February 20, 1956)
	Sethi, R. et al., "Differential changes in left and right ventricular adenylyl cyclase activities in congestive heart failure", <i>The American Physiological Society</i> , Vol. 272, No. 2, Part 2 of Two Parts, pp. H884 - H893 (February 1997)
	Sethi, R. et al., "Inotropic Responses to Isoproterenol in Congestive Heart Failure Subsequent to Myocardial Infarction in Rats", <i>Journal of Cardiac Failure</i> , Vol. 1, No. 5, pp. 391 - 399 (December 1995)
	Stirtan, W. et al., "Phosphonate and Fluorophosphonate Analogue Probes of the Ionization State of Pyridoxal 5'-Phosphate (PLP) in Glycogen Phosphorylase", <i>Biochemistry</i> , Vol. 35, No. 47, pp. 15057-15064 (1996)
	Takuma, Y. et al., "Combination Therapy of Infantile Spasms With High-Dose Pyridoxal Phosphate and Low-Dose Corticotropin", <i>Journal of Child Neurology</i> , Vol. 11, No. 1, pp. 35-40 (January 1996).
	Tanaka, T. et al., "Pyridoxine Derivatives", <i>Chemical Abstracts</i> , Vol. 62, No. 12, 1 page (June 7, 1965)
	Tomita, I. et al., "SYNthesis of Vitamin B <sub>6</sub> Derivatives. II 3-Hydroxy-4-Hydroxymethyl-2-Methyl-5-Pyridine Acetic Acid and Related Substances", <i>Dept. of Biochem. and Biophys., Iowa State Univ.</i> , Vol. 3, pp. 178-183 (1996)
	Treize, D. et al., "P <sub>2</sub> purinoceptor antagonist properties of pyridoxal-5-phosphate", <i>Eur. J. Pharmacol.</i> , Vol. 259, No. 3, pp. 295-300 (July 11, 1994)
	Vanderjagt, D. et al., "Vitamin B <sub>6</sub> Status in a Healthy Elderly Population", <i>Annals New York Academy of Sciences</i> , pp. 562 - 564 (date unknown)
	Verhoef, P. et al., "A Common Mutation in the Methylenetetrahydrofolate Reductase Gene and Risk of Coronary Heart Disease: Results Among U.S. Men", <i>JACC</i> , Vol. 32, No. 2, pp. 353 -359 (August 1998)
	Verhoef, P. et al., "Homocysteine Metabolism and Risk of Myocardial Infarction: Relation with Vitamins B <sub>6</sub> , B <sub>12</sub> , and Folate", <i>Am. J. Epidemiol.</i> , Vol. 143, No. 9, pp. 845-859 (May 1, 1996)
	Vermaak, W.J.H. et al., "Vitamin B <sub>6</sub> and coronary artery disease. Epidemiological observations and case studies", <i>Atherosclerosis</i> , Vol. 63, pp. 235-238 (February 1987)
	Vidrio, H., "Interaction with Pyridoxal as a Possible Mechanism of Hydralazine Hypotension", <i>Journal of Cardiovascular Pharmacology</i> , Vol. 15, pp. 150-156 (1990).
	Viscontini, V. et al., "Über einige Derivate des Pyridoxals", <i>Helvetica Chimica Acta</i> , Vol. 34, No. 296, pp. 2438-2439 (1951)
	Windebank, A., "Neurotoxicity of Pyridoxine Analogs Is Related to Coenzyme Structure", <i>Neurochemical Pathology</i> , Vol. 3, pp. 159-167 (1985)
	Yan, S. et al., "A Role for Pyridoxal Phosphate in the Control of Dephosphorylation of Phosphorylase $\alpha$ ", <i>J. of Biological Chem.</i> , Vol. 254, No. 17, pp. 8263-8269 (1979)
	Yarat, A. et al., "Effect of vitamin B <sub>6</sub> on lenses of diabetic rats", <i>Indian Journal of Experimental Biology</i> , Vol. 36, pp. 1269-1272 (December 1998)
	Zempleni, J. et al., "The utilization of intravenously infused pyridoxine in humans", <i>Clinica Chimica Acta</i> , Vol. 229, Nos. 1, 2, pp. 27-36 (September 1994)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CA/

EXAMINER /Charanjit Aulakh/	DATE CONSIDERED 05/08/2008
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	